← Oncology Approval Tracker

FDA DECISION ·

Crysvita

burosumab-twza · Kyowa Kirin

FDA approvalNew or expanded indicationTumor-induced osteomalacia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children ages two and older with FGF23-related hypophosphatemia from tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that could not be located or curatively resected.

LAMPGEN ANALYSIS

Why it matters

Addressed the phosphate-wasting complication of a tumor when definitive tumor removal was unavailable.

What research teams should watch

Coordinate tumor localization and phosphate testing with metabolic bone specialists.

PRIMARY RECORDS

Sources